文献速递甲状腺核医学核素与放射性配体治疗

滤泡状甲状腺癌肺转移灶对碘-131治疗反应显著而残留甲状腺组织持续显影

Remarkable Response of Pulmonary Metastases Rather Than Remnant Thyroid in 131I Therapy of Follicular Thyroid Cancer.
PubMed 文献 · Clin Nucl Med · 2019-01-01

一例66岁男性滤泡状甲状腺癌全切除术后患者,未服左甲状腺素却出现严重甲状腺毒症。碘-131全身显像及SPECT/CT发现多发摄碘肺转移灶(最大径1.4 cm)及残留甲状腺,诊断为功能性肺转移灶所致甲状腺毒症。给予7.4 GBq碘-131治疗后6个月,肺转移灶显著缩小、甲状腺球蛋白下降,但残留甲状腺仍显影。

要点

  • 功能性肺转移灶可致甲状腺毒症,甲状腺切除术后未服左甲状腺素者需警惕。
  • 碘-131治疗6个月后肺转移灶显著缩小且甲状腺球蛋白下降。
  • 残留甲状腺组织在碘-131治疗后6个月仍持续显影。

核心结论

  • 滤泡状甲状腺癌的功能性肺转移灶可导致甲状腺毒症,碘-131治疗后肺转移灶反应显著而残留甲状腺持续显影。

研究设计与样本

  • 单例病例报告:66岁男性滤泡状甲状腺癌全切除术后患者。

主要发现

  • 碘给药前甲状腺功能检查显示严重甲状腺毒症,患者甲状腺切除术后未服左甲状腺素。
  • 185 MBq碘-131全身显像及SPECT/CT显示多发摄碘肺转移灶,最大肿瘤直径1.4 cm,并见残留甲状腺。
  • 给予7.4 GBq碘-131治疗6个月后,肺转移病变显著减少且甲状腺球蛋白水平下降,但残留甲状腺仍显影。

关键数值与推荐

  • 碘-131治疗剂量为7.4 GBq;诊断性显像剂量为185 MBq。
  • 肺转移灶最大肿瘤直径为1.4 cm。

临床怎么用

  • 甲状腺癌术后未服左甲状腺素而出现甲状腺毒症时,应警惕功能性转移灶可能,可行碘-131显像评估。
  • 对摄碘性肺转移灶可考虑碘-131治疗,但需注意残留甲状腺可能持续显影。

局限性

  • 单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 66-year-old man with follicular thyroid cancer after total thyroidectomy was referred for I therapy. Thyroid function tests before I administration exhibited severe thyrotoxicosis although the patient did not take levothyroxine after thyroidectomy. A 185 MBq I whole-body scintigraphy and SPECT/CT revealed multiple iodine-avid pulmonary metastases with the largest tumor diameter of 1.4 cm and remnant thyroid. A diagnosis of thyrotoxicosis caused by hyperfunctioning pulmonary metastases was then made. The patient was administered 7.4 GBq of I. Six months after I therapy, a significant reduction of the pulmonary metastatic disease and thyroglobulin level was observed. However, the remnant thyroid was still visualized.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tian T, Chen Y, Xiang Y, et al. Remarkable Response of Pulmonary Metastases Rather Than Remnant Thyroid in 131I Therapy of Follicular Thyroid Cancer. Clin Nucl Med. 2019. PMID: 30688748. doi:10.1097/RLU.0000000000002477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。